MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock through...
$4,825K
Net cash provided by
financing activities
$4,825K
(-67.95%↓ Y/Y)
Increase (decrease) in
cash, cash...
-$5,139K
(37.88%↑ Y/Y)
Canceled cashflow
$4,825K
Other current assets
-$474K
(92.37%↑ Y/Y)
Stock-based compensation
expense
$394K
(-94.38%↓ Y/Y)
Other current
liabilities
$247K
(117.18%↑ Y/Y)
Non-cash operating lease
expense
$191K
(-95.67%↓ Y/Y)
Accounts payable
$187K
(106.10%↑ Y/Y)
Accretion of liability
related to sale of future...
$173K
(-90.44%↓ Y/Y)
Other assets
-$125K
(-3225.00%↓ Y/Y)
Deferred revenue
$91K
(100.10%↑ Y/Y)
Accrued compensation
$70K
(101.73%↑ Y/Y)
Other non-cash items,
net
$51K
(-90.68%↓ Y/Y)
Other long-term
liabilities
$21K
(2000.00%↑ Y/Y)
Accrued research and
development expenses
$16K
(100.23%↑ Y/Y)
Depreciation and
amortization expense
$14K
(-99.31%↓ Y/Y)
Net cash (used in)
provided by investing...
-$6,626K
(-154.63%↓ Y/Y)
Net cash used in
operating activities
-$3,338K
(90.59%↑ Y/Y)
Canceled cashflow
$2,054K
Purchases of short-term
investments
$6,626K
(22.27%↑ Y/Y)
Net income (loss)
-$4,834K
(-111.97%↓ Y/Y)
Accounts receivable
$318K
(121.46%↑ Y/Y)
Operating lease
liabilities
-$211K
(94.96%↑ Y/Y)
Amortization (accretion) of
investment premiums...
$29K
(111.24%↑ Y/Y)
Back
Back
Cash Flow
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)
source: myfinsight.com